SCHEMBL6307609

SCHEMBL6307609

CCOC(=O)c1cc2c(-c3ccc(Cl)cc3)cccc2n1Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 11/20 0.65
MAPT P10636 3/20 0.53
KDM4E B2RXH2 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
MAPK1 P28482 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
F10 P00742 3/20 0.50
LMNA P02545 1/20 0.50
GAA P10253 1/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NOD2 Q9HC29 1/20 0.50
NOD1 Q9Y239 1/20 0.50
MDM2 Q00987 1/20 0.44
ALDH1A1 P00352 2/20 0.44
POLB P06746 1/20 0.44
TSHR P16473 1/20 0.44
ATM Q13315 1/20 0.44
MEN1 O00255 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6302517 0.93 CCR2 (0.76) CCR2MAPTTDP1F10LMNA
SCHEMBL6307184 0.92 CCR2 (0.62) CCR2MAPTKDM4ETDP1MAPK1
SCHEMBL7088867 0.91 CCR2 (0.61) CCR2MAPTKDM4ETDP1MAPK1
SCHEMBL6307935 0.90 CCR2 (0.60) CCR2MAPTKDM4ETDP1MAPK1
SCHEMBL6303386 0.89 CCR2 (0.64) CCR2MAPTKDM4ETDP1MAPK1
SCHEMBL6307845 0.89 CCR2 (0.61) CCR2MAPTF10LMNAGAA
SCHEMBL6300756 0.88 CCR2 (0.62) CCR2MAPTKDM4ETDP1MAPK1
SCHEMBL6307932 0.87 CCR2 (0.61) CCR2MAPTKDM4ETDP1MAPK1
SCHEMBL6307953 0.87 CCR2 (0.58) CCR2MAPTKDM4ETDP1MAPK1
SCHEMBL6300925 0.87 CCR2 (0.71) CCR2MAPTKDM4ETDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6953809-B2 Monocyte chemoattractant protein-1 inhibitor compounds ZENECA LIMITED (GB) 2005-10-11 US disclosed
US-20030119830-A1 Monocyte chemoattractant protein-1 inhibitor compounds ZENECA LIMITED 2003-06-26 US disclosed
US-6441004-B1 INDOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS ZENECA LIMITED (GB) 2002-08-27 US disclosed
EP-1003504-A2 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS AstraZeneca UK Limited (GB) 2000-05-31 EP disclosed
WO-1999007351-A2 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS ZENECA LIMITED (GB) 1999-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119830-A1 Monocyte chemoattractant protein-1 inhibitor compounds CCL2, CCL11, CCR1 CCR2 4/4885MAPT 2876/4885KDM4E 3717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.